All News

The need for data-driven, multidisciplinary care and the critical role of pharmacists in managing the growing complexity of oncology treatment

Pharmacists are enabling the shift to outpatient bispecific antibody care through education, SOP development, and care coordination.

Cardinal Health’s 2026 Advanced Therapies Report found strong provider momentum for expanding advanced therapy administration into community settings.

GoodRx CCO Laura Jensen discusses how e-commerce, GLP-1 demand, and a fragmented health care system are driving a new era of direct-to-patient, cash-based pharmacy access.

This quiz was created in collaboration with PTCE™.

Harm reduction–based counseling frameworks for cannabis use during pregnancy and lactation can improve patient engagement, disclosure, and safety, with pharmacists playing a key role in implementation.

COA 2026 reveals how bispecific antibodies transform lymphoma care—outpatient workflows, SOPs, and infection vigilance shape safe BTCE delivery.

Postate cancer care shifts toward personalized, team-based management in an increasingly complex therapeutic landscape.

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 1.3 billion people globally, driven by metabolic disease trends, highlighting urgent needs for earlier detection, prevention, and pharmacist-led intervention.

Pharmacists are central to implementing bispecific antibody therapies through clinical expertise, operational leadership, and care coordination.

Fran Gregory, PharmD, outlines the expanding landscape of advanced therapies and the pivotal role specialty pharmacies play in bringing these complex treatments to community-based providers and patients.

Pharmacists support evidence-based treatment decisions, coordinate multidisciplinary care, and optimize precision oncology outcomes.

In a session at the Asembia AXS26 Summit, Harry Travis discusses how AI is transforming every step of the prescription process faster than the profession is prepared for.

Integrated EMR systems and coordinated pharmacy operations can streamline biomarker-driven treatment decisions and improve patient outcomes.

Symptom-based dosing reduced time to medical readiness for discharge compared with scheduled opioid, without increasing short-term safety risks.

Pharmacy learner–led opioid overdose and naloxone training significantly improved community preparedness and confidence in responding to opioid overdoses.

Pharmacists play a crucial role in the treatment of patients with chronic myeloid leukemia (CML) taking tyrosine kinase inhibitors.

Pharmacists can help standardize biomarker testing and improve access to targeted therapies in non–small cell lung cancer.

The approval follows positive results from a phase 3 randomized withdrawal trial.

Pharmacists can help optimize TKI therapy in CML through education, adherence support, toxicity monitoring, and collaboration with care teams.

CAR T drives deep remissions in myeloma and lymphoma, but payers, staffing, and hospital partners shape timely community access.

NABP’s new uniform pharmacy law exam streamlines multistate licensure, reshapes MPJE prep, and speeds pharmacist mobility in 2026.

Bispecific antibodies are reshaping multiple myeloma care through improved safety and expanded outpatient use.

At AXS2026, pharmacy and health care leaders explored how AI is transforming specialty care and why standards, trust, and oversight must keep pace with innovation.

Integrated health plan–provider collaboration enables pharmacists to drive proactive diabetes management, improve adherence, and expand access to CGM and lifestyle support.

2026 dyslipidemia guideline updates highlight earlier risk-based lipid management, expanded biomarker use, and a growing pharmacist role in cardiovascular prevention.

The rare disease space is an area where scientific rigor meets genuine human impact.

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.